<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226966</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-3815</org_study_id>
    <secondary_id>U1111-1116-2722</secondary_id>
    <nct_id>NCT01226966</nct_id>
  </id_info>
  <brief_title>Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes</brief_title>
  <acronym>EVIDENCE</acronym>
  <official_title>Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study is conducted in Europe. The aim of this non-interventional
      (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the
      conditions of use of Victoza® in daily medical practice in France.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%</measure>
    <time_frame>Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at month 3</measure>
    <time_frame>Month 0, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at month 6</measure>
    <time_frame>Month 0, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at month 12</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at month 18</measure>
    <time_frame>Month 0, Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at month 24</measure>
    <time_frame>Month 0, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) at month 3</measure>
    <time_frame>Month 0, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) at month 6</measure>
    <time_frame>Month 0, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) at month 12</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) at month 18</measure>
    <time_frame>Month 0, Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) at month 24</measure>
    <time_frame>Month 0, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 3</measure>
    <time_frame>Month 0, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 6</measure>
    <time_frame>Month 0, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 12</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 18</measure>
    <time_frame>Month 0, Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight at Month 24</measure>
    <time_frame>Month 0, Month 24</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3152</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients starting or having recently started liraglutide treatment for less than one week,
        and satisfying the study inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with type 2 diabetes

          -  Patients having recently started (for less than one week) or starting liraglutide
             (Victoza®) treatment

        Exclusion Criteria:

          -  Hypersensitivity (allergy) to liraglutide or to any of the excipients

          -  Patient is participating in a clinical trial at the inclusion

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452), Medical Advisor</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris La défense cedex</city>
        <zip>92932</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Gautier JF, Martinez L, Penfornis A, Eschwège E, Charpentier G, Huret B, Madani S, Gourdy P. Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study. Adv Ther. 2015 Sep;32(9):838-53. doi: 10.1007/s12325-015-0245-x. Epub 2015 Sep 30.</citation>
    <PMID>26424330</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez L, Penfornis A, Gautier JF, Eschwège E, Charpentier G, Bouzidi A, Gourdy P. Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study. Adv Ther. 2017 Mar;34(3):674-685. doi: 10.1007/s12325-017-0476-0. Epub 2017 Jan 30.</citation>
    <PMID>28138803</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

